Why is Medicamen Biotec falling/rising?

As of 11-Jul, Medicamen Biotech Ltd is currently priced at Rs 393.00, reflecting a slight increase of 0.1 (0.03%). The stock has recently shown a trend reversal, gaining after three consecutive days of decline. However, it remains 4.07% away from its 52-week low and has underperformed its sector by 0.55%. Over the past week, the stock has decreased by 2.24%, and its performance over the last month shows a decline of 7.45%. Notably, the company has a low Debt to Equity ratio, but its operating profit has decreased at an annual rate of -16.39% over the last five years, contributing to a negative outlook. The stock's return on capital employed (ROCE) is low at 5.30%, and its cash and cash equivalents are at their lowest, indicating financial strain.
In the broader market context, the stock has consistently underperformed against the benchmark, with a year-to-date return of -22.83% compared to the Sensex's gain of 5.58%. The stock's performance has lagged behind the BSE500 in each of the last three annual periods, highlighting its ongoing struggles. Despite being liquid enough for trading, the falling investor participation, with a significant drop in delivery volume, suggests a lack of confidence among investors. Overall, while there is a minor uptick in price, the underlying fundamentals and market performance indicate a challenging environment for Medicamen Biotech Ltd.